SKYE Stock Forecast & Price Target

Skye Bioscience Inc. is focused on innovative treatments targeting metabolic disorders, primarily through its clinical assets, including nimacimab and SBI-100 Ophthalmic Emulsion. The company shows promise with nimacimab, as its potential expansion into metabolic liver disease and associated biomarker improvements, such as liver fat reduction and enhanced insulin sensitivity, indicate a broader therapeutic value beyond its initial applications. Additionally, nimacimab's gastrointestinal tolerability suggests a competitive advantage over current therapies, potentially leading to improved patient adherence and positive long-term outcomes.

Skye Bioscience Inc has consistently incurred operating losses since its inception, indicating a challenging pathway to achieving profitability in the near future. The potential outcome of limited efficacy or safety concerns during the Phase 2a trial for nimacimab raises significant apprehensions regarding the viability of this asset for obesity treatment, which could lead to a substantial decline in stock value. Furthermore, there are notable translational gaps related to safety and tolerability for CB1 antagonists, particularly due to their extensive penetration in the central nervous system, complicating the company's future prospects.